CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-02-21
DOI
10.3389/fphar.2019.01662
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Challenges Facing Airway Epithelial Cell-Based Therapy for Cystic Fibrosis
- (2019) Andrew Berical et al. Frontiers in Pharmacology
- Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis
- (2019) Gitte Berkers et al. Cell Reports
- In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis
- (2019) Xingshen Sun et al. Science Translational Medicine
- Decreased mRNA and protein stability of W1282X limits response to modulator therapy
- (2019) M.A. Aksit et al. Journal of Cystic Fibrosis
- Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines
- (2019) Kathleen J. Ramos et al. Journal of Cystic Fibrosis
- Pharmacokinetic and Drug-Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor
- (2019) Varun Garg et al. CTS-Clinical and Translational Science
- Nonsense Mediated RNA Decay Pathway Inhibition Restores Expression and Function of W1282X CFTR
- (2019) Melissa M Keenan et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Correlating CFTR Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis
- (2019) Allison F McCague et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- The Cystic Fibrosis-Like Airway Surface Layer Is not a Significant Barrier for Delivery of Eluforsen to Airway Epithelial Cells
- (2019) Vera Brinks et al. Journal of Aerosol Medicine and Pulmonary Drug Delivery
- GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1)
- (2019) Jane C. Davies et al. Journal of Cystic Fibrosis
- CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials
- (2019) Scott C. Bell et al. Journal of Cystic Fibrosis
- An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2–5 years (KLIMB)
- (2019) Margaret Rosenfeld et al. Journal of Cystic Fibrosis
- Identification of GLPG/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy With Other CFTR Modulators
- (2019) Gert de Wilde et al. Frontiers in Pharmacology
- Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study
- (2019) John J McNamara et al. Lancet Respiratory Medicine
- High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs
- (2019) Sylvia Merkert et al. Stem Cell Reports
- High-Throughput Surface Liquid Absorption and Secretion Assays to Identify F508del CFTR Correctors Using Patient Primary Airway Epithelial Cultures
- (2019) Allison Berg et al. SLAS Discovery
- [PROVISIONAL] Determining the Pathogenicity of CFTR Missense Variants: Multiple Comparison of in silico Predictors and Variant Annotation Databases
- (2019) Marcus Michels et al. GENETICS AND MOLECULAR BIOLOGY
- Theranostics by testing CFTR modulators in patient-derived materials: The current status and a proposal for subjects with rare CFTR mutations
- (2019) Margarida D. Amaral et al. Journal of Cystic Fibrosis
- Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery
- (2019) Jane C. Davies et al. Journal of Cystic Fibrosis
- A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis
- (2019) Seth Walker et al. Journal of Cystic Fibrosis
- Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770
- (2019) Han-I Yeh et al. JOURNAL OF GENERAL PHYSIOLOGY
- Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis
- (2019) Wouter Beumer et al. PLoS One
- Structural identification of a hotspot on CFTR for potentiation
- (2019) Fangyu Liu et al. SCIENCE
- A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis
- (2019) Al-Rahim R. Habib et al. Scientific Reports
- Novel, rare and common pathogenic variants in the CFTR gene screened by high-throughput sequencing technology and predicted by in silico tools
- (2019) Stéphanie Villa-Nova Pereira et al. Scientific Reports
- Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity
- (2019) Andrea Armirotti et al. Scientific Reports
- CK19 stabilizes CFTR at the cell surface by limiting its endocytic pathway degradation
- (2019) Xia Hou et al. FASEB JOURNAL
- Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis
- (2019) Pierre-Régis Burgel et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Slowing ribosome velocity restores folding and function of mutant CFTR
- (2019) Kathryn E. Oliver et al. JOURNAL OF CLINICAL INVESTIGATION
- GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN)
- (2019) Silke van Koningsbruggen-Rietschel et al. Journal of Cystic Fibrosis
- Mutation-specific dual potentiators maximize rescue of CFTR gating mutants
- (2019) Guido Veit et al. Journal of Cystic Fibrosis
- Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222
- (2019) Ashvani K. Singh et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
- (2019) Harry G M Heijerman et al. LANCET
- Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
- (2019) Peter G. Middleton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis
- (2019) Marc J. C. Scanio et al. ACS Medicinal Chemistry Letters
- VX-770-mediated potentiation of numerous human CFTR disease mutants is influenced by phosphorylation level
- (2019) Guiying Cui et al. Scientific Reports
- Editorial: Emerging Therapeutic Approaches for Cystic Fibrosis
- (2019) Miquéias Lopes-Pacheco et al. Frontiers in Pharmacology
- Vx-809/Vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells
- (2018) Manon Ruffin et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Effects of Lumacaftor–Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis
- (2018) Simon Y. Graeber et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR
- (2018) Scott H. Donaldson et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Cystic Fibrosis Disease Modifiers: Complex Genetics Defines the Phenotypic Diversity in a Monogenic Disease
- (2018) Wanda K. O'Neal et al. Annual Review of Genomics and Human Genetics
- The CFTR-Associated Ligand Arrests the Trafficking of the Mutant ΔF508 CFTR Channel in the ER Contributing to Cystic Fibrosis
- (2018) Emily Bergbower et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- CORK Study in Cystic Fibrosis
- (2018) Nicola J. Ronan et al. CHEST
- Chaperone-Independent Peripheral Quality Control of CFTR by RFFL E3 Ligase
- (2018) Tsukasa Okiyoneda et al. DEVELOPMENTAL CELL
- The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease
- (2018) Patrick J. Moore et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy
- (2018) Gizem Osman et al. JOURNAL OF CONTROLLED RELEASE
- Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation
- (2018) Aaron T. Trimble et al. Journal of Cystic Fibrosis
- Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR
- (2018) Jennifer L. Taylor-Cousar et al. Journal of Cystic Fibrosis
- Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D - CFTR mutation treated with ivacaftor
- (2018) Patrick A. Flume et al. Journal of Cystic Fibrosis
- R560S: A class II CFTR mutation that is not rescued by current modulators
- (2018) Nikhil T. Awatade et al. Journal of Cystic Fibrosis
- Combination potentiator (‘co-potentiator’) therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators
- (2018) Puay-Wah Phuan et al. Journal of Cystic Fibrosis
- ECFS best practice guidelines: the 2018 revision
- (2018) Carlo Castellani et al. Journal of Cystic Fibrosis
- Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis
- (2018) Xueqing Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of N-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent
- (2018) Steven E. Van der Plas et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Proteomic Variant Approach (ProVarA) for Personalized Medicine of Inherited and Somatic Disease
- (2018) Darren M. Hutt et al. JOURNAL OF MOLECULAR BIOLOGY
- Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations
- (2018) Virginia A. Stallings et al. JOURNAL OF PEDIATRICS
- Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains
- (2018) Onofrio Laselva et al. MOLECULAR PHARMACOLOGY
- Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
- (2018) Leona Bessonova et al. THORAX
- Pluripotent Stem Cell Platforms for Drug Discovery
- (2018) Kevin G. Chen et al. TRENDS IN MOLECULAR MEDICINE
- Orphan Drugs and Their Impact on Pharmaceutical Development
- (2018) Misty M. Attwood et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Economic Modeling Considerations for Rare Diseases
- (2018) Isobel Pearson et al. VALUE IN HEALTH
- Sites associated with Kalydeco binding on human Cystic Fibrosis Transmembrane Conductance Regulator revealed by Hydrogen/Deuterium Exchange
- (2018) Laura J. Byrnes et al. Scientific Reports
- Ivacaftor treatment of cystic fibrosis in children aged 12 to
- (2018) Margaret Rosenfeld et al. Lancet Respiratory Medicine
- An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene Therapy
- (2018) Gregg A. Duncan et al. Molecular Therapy-Methods & Clinical Development
- Islet Hormone and Incretin Secretion in Cystic Fibrosis Following 4-months of Ivacaftor Therapy
- (2018) Andrea Kelly et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis
- (2018) Philip Farrell et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function
- (2018) Karin M. de Winter-de Groot et al. EUROPEAN RESPIRATORY JOURNAL
- Self-complementary and tyrosine-mutant rAAV vectors enhance transduction in cystic fibrosis bronchial epithelial cells
- (2018) Miquéias Lopes-Pacheco et al. EXPERIMENTAL CELL RESEARCH
- Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1
- (2018) Susanna A. McColley et al. Journal of Cystic Fibrosis
- Structure-guided combination therapy to potently improve the function of mutant CFTRs
- (2018) Guido Veit et al. NATURE MEDICINE
- Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States
- (2018) Dolly Sharma et al. Orphanet Journal of Rare Diseases
- Prolonged co-treatment with HGF sustains epithelial integrity and improves pharmacological rescue of Phe508del-CFTR
- (2018) Ana M. Matos et al. Scientific Reports
- SLC26A9 Gene Is Associated With Lung Function Response to Ivacaftor in Patients With Cystic Fibrosis
- (2018) Harriet Corvol et al. Frontiers in Pharmacology
- Peripheral Protein Quality Control as a Novel Drug Target for CFTR Stabilizer
- (2018) Ryosuke Fukuda et al. Frontiers in Pharmacology
- Might Brushed Nasal Cells Be a Surrogate for CFTR Modulator Clinical Response?
- (2018) Iwona Pranke et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Cryo-EM Visualization of an Active High Open Probability CFTR Anion Channel
- (2018) Jonathan F. Fay et al. BIOCHEMISTRY
- Increases in cytosolic Ca2+ induce dynamin- and calcineurin-dependent internalisation of CFTR
- (2018) Waseema Patel et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- The cystic fibrosis airway milieu enhances rescue of F508del in a pre-clinical model
- (2018) Martina Gentzsch et al. EUROPEAN RESPIRATORY JOURNAL
- The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: a basis for read‐through therapies in cystic fibrosis
- (2018) Luka A. Clarke et al. HUMAN MUTATION
- Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis
- (2018) Isabelle Sermet-Gaudelus et al. Journal of Cystic Fibrosis
- Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis
- (2018) Patrick A. Flume et al. Journal of Cystic Fibrosis
- Drug repurposing: progress, challenges and recommendations
- (2018) Sudeep Pushpakom et al. NATURE REVIEWS DRUG DISCOVERY
- VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
- (2018) Dominic Keating et al. NEW ENGLAND JOURNAL OF MEDICINE
- VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
- (2018) Jane C. Davies et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular structure of the ATP-bound, phosphorylated human CFTR
- (2018) Zhe Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis
- (2018) Neeraj Sharma et al. PLoS Genetics
- Cell Therapy for Cystic Fibrosis Lung Disease: Regenerative Basal Cell Amplification
- (2018) Don Hayes et al. Stem Cells Translational Medicine
- Identification and Characterization of Novel CFTR Potentiators
- (2018) Maarten Gees et al. Frontiers in Pharmacology
- Variable Responses to CFTR Correctors in vitro: Estimating the Design Effect in Precision Medicine
- (2018) Elizabeth Matthes et al. Frontiers in Pharmacology
- Role of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic Fibrosis
- (2018) Anita Balázs et al. Frontiers in Pharmacology
- Gene Therapy for Cystic Fibrosis Lung Disease: Overcoming the Barriers to Translation to the Clinic
- (2018) Martin Donnelley et al. Frontiers in Pharmacology
- Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine
- (2018) Nikhil T. Awatade et al. Frontiers in Pharmacology
- Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences
- (2017) Xiaojiao Xue et al. HUMAN MOLECULAR GENETICS
- Mutation-specific downregulation of CFTR2 variants by gating potentiators
- (2017) Radu G Avramescu et al. HUMAN MOLECULAR GENETICS
- Brazilian guidelines for the diagnosis and treatment of cystic fibrosis
- (2017) Rodrigo Abensur Athanazio et al. Jornal Brasileiro de Pneumologia
- High-throughput screening identifies FAU protein as a regulator of mutant cystic fibrosis transmembrane conductance regulator channel
- (2017) Valeria Tomati et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F 508 DEL - CFTR
- (2017) Scott H. Donaldson et al. Journal of Cystic Fibrosis
- Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation
- (2017) Venkateshwar Mutyam et al. Journal of Cystic Fibrosis
- A common mechanism for CFTR potentiators
- (2017) Han-I Yeh et al. JOURNAL OF GENERAL PHYSIOLOGY
- Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development
- (2017) Scott L. Harbeson et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Direct Binding of the Corrector VX-809 to Human CFTR NBD1: Evidence of an Allosteric Coupling between the Binding Site and the NBD1:CL4 Interface
- (2017) Rhea P. Hudson et al. MOLECULAR PHARMACOLOGY
- Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis
- (2017) Luigina Romani et al. NATURE MEDICINE
- Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
- (2017) Steven M. Rowe et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
- (2017) Jennifer L. Taylor-Cousar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overcoming barriers to a successful transition from pediatric to adult care
- (2017) Jennifer L. Goralski et al. PEDIATRIC PULMONOLOGY
- In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies
- (2017) Meghan E. McGarry et al. PEDIATRIC PULMONOLOGY
- Current and emerging comorbidities in cystic fibrosis
- (2017) Nicola J. Ronan et al. PRESSE MEDICALE
- Clinical Trials in a Dish
- (2017) David G. Strauss et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators
- (2017) Iwona M. Pranke et al. Scientific Reports
- Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial
- (2017) Felix Ratjen et al. Lancet Respiratory Medicine
- Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study
- (2017) Michael W Konstan et al. Lancet Respiratory Medicine
- Adherence to therapies in cystic fibrosis: a targeted literature review
- (2017) Siva Narayanan et al. Expert Review of Respiratory Medicine
- Use of a High-Throughput Phenotypic Screening Strategy to Identify Amplifiers, a Novel Pharmacological Class of Small Molecules That Exhibit Functional Synergy with Potentiators and Correctors
- (2017) Kenneth A. Giuliano et al. SLAS Discovery
- High-Throughput Screening for Readthrough Modulators of CFTR PTC Mutations
- (2017) Feng Liang et al. SLAS Technology
- Augmentation of CFTR maturation by S-nitrosoglutathione reductase
- (2016) Khalequz Zaman et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations
- (2016) Venkateshwar Mutyam et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor)
- (2016) Elizabeth Matthes et al. BRITISH JOURNAL OF PHARMACOLOGY
- A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR
- (2016) A Tosco et al. CELL DEATH AND DIFFERENTIATION
- Role of CFTR in epithelial physiology
- (2016) Vinciane Saint-Criq et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Correctors Rescue CFTR Mutations in Nucleotide-Binding Domain 1 (NBD1) by Modulating Proteostasis
- (2016) Miquéias Lopes-Pacheco et al. CHEMBIOCHEM
- The psychological burden of cystic fibrosis
- (2016) Alexandra L. Quittner et al. CURRENT OPINION IN PULMONARY MEDICINE
- Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids
- (2016) Johanna F. Dekkers et al. EUROPEAN RESPIRATORY JOURNAL
- Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis
- (2016) Caitlyn T. Solem et al. Health and Quality of Life Outcomes
- Cystic fibrosis gene modifierSLC26A9modulates airway response to CFTR-directed therapeutics
- (2016) Lisa J. Strug et al. HUMAN MOLECULAR GENETICS
- Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product
- (2016) Peter M. Haggie et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- EPAC1 activation by cAMP stabilizes CFTR at the membrane by promoting its interaction with NHERF1
- (2016) Miguel J. Lobo et al. JOURNAL OF CELL SCIENCE
- Bone demineralization is improved by ivacaftor in patients with cystic fibrosis carrying the p.Gly551Asp mutation
- (2016) Isabelle Sermet-Gaudelus et al. Journal of Cystic Fibrosis
- CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation
- (2016) Reuven Tsabari et al. Journal of Cystic Fibrosis
- The novel complex allele [A238V;F508del] of the CFTR gene: clinical phenotype and possible implications for cystic fibrosis etiological therapies
- (2016) Anna Diana et al. JOURNAL OF HUMAN GENETICS
- From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations
- (2016) Gudio Veit et al. MOLECULAR BIOLOGY OF THE CELL
- Potentiation of ΔF508- and G551D-CFTR-Mediated Cl- Current by Novel Hydroxypyrazolines
- (2016) Jinhong Park et al. PLoS One
- Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis
- (2016) Johanna F. Dekkers et al. Science Translational Medicine
- Cystic fibrosis drug is not cost effective, says NICE
- (2016) Anne Gulland BMJ-British Medical Journal
- Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect
- (2016) Guido Veit et al. PLOS BIOLOGY
- Cystic fibrosis drug is not cost effective, says NICE
- (2016) Anne Gulland BMJ-British Medical Journal
- CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis
- (2016) Miquéias Lopes-Pacheco Frontiers in Pharmacology
- Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis
- (2016) Ellison D. Suthoff et al. JOURNAL OF MEDICAL ECONOMICS
- Treatment of cystic fibrosis in low-income countries
- (2016) Malena Cohen-Cymberknoh et al. Lancet Respiratory Medicine
- Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study
- (2016) Jane C Davies et al. Lancet Respiratory Medicine
- Classification of CFTR mutation classes
- (2016) Fernando Augusto Lima Marson et al. Lancet Respiratory Medicine
- Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis
- (2016) J Stuart Elborn et al. Lancet Respiratory Medicine
- Progress in therapies for cystic fibrosis
- (2016) Kris De Boeck et al. Lancet Respiratory Medicine
- Socioeconomic status and health outcomes: cystic fibrosis as a model
- (2016) Gabriela R. Oates et al. Expert Review of Respiratory Medicine
- Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data
- (2015) Gregory S. Sawicki et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Precision Medicine: At What Price?
- (2015) Thomas Ferkol et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor
- (2015) Drucy Borowitz et al. DIGESTIVE DISEASES AND SCIENCES
- Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial
- (2015) Alexandra Quittner et al. Health and Quality of Life Outcomes
- Socio-economic burden of rare diseases: A systematic review of cost of illness evidence
- (2015) Aris Angelis et al. HEALTH POLICY
- Correction of a Cystic Fibrosis Splicing Mutation by Antisense Oligonucleotides
- (2015) Susana Igreja et al. HUMAN MUTATION
- Rescuing Trafficking Mutants of the ATP-binding Cassette Protein, ABCA4, with Small Molecule Correctors as a Treatment for Stargardt Eye Disease
- (2015) Inna Sabirzhanova et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Combination of Correctors Rescue ΔF508-CFTR by Reducing Its Association with Hsp40 and Hsp27
- (2015) Miquéias Lopes-Pacheco et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor
- (2015) Christopher M. Siracusa et al. Journal of Cystic Fibrosis
- Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking
- (2015) Graeme W. Carlile et al. Journal of Cystic Fibrosis
- ∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis
- (2015) Sandra Pankow et al. NATURE
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
- (2015) Claire E. Wainwright et al. NEW ENGLAND JOURNAL OF MEDICINE
- A five-year retrospective analysis of adherence in cystic fibrosis
- (2015) Aarti Shakkottai et al. PEDIATRIC PULMONOLOGY
- A molecular switch in the scaffold NHERF1 enables misfolded CFTR to evade the peripheral quality control checkpoint
- (2015) Cláudia A. Loureiro et al. Science Signaling
- Genetic Inhibition Of The Ubiquitin Ligase Rnf5 Attenuates Phenotypes Associated To F508del Cystic Fibrosis Mutation
- (2015) Valeria Tomati et al. Scientific Reports
- A molecular switch in the scaffold NHERF1 enables misfolded CFTR to evade the peripheral quality control checkpoint
- (2015) Cláudia A. Loureiro et al. Science Signaling
- Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis
- (2015) Nikhil T. Awatade et al. EBioMedicine
- Rescue of NBD2 Mutants N1303K and S1235R of CFTR by Small-Molecule Correctors and Transcomplementation
- (2015) Daniele Rapino et al. PLoS One
- Pseudomonas aeruginosa Reduces VX-809 Stimulated F508del-CFTR Chloride Secretion by Airway Epithelial Cells
- (2015) Bruce A. Stanton et al. PLoS One
- VIP regulates CFTR membrane expression and function in Calu-3 cells by increasing its interaction with NHERF1 and P-ERM in a VPAC1- and PKCε-dependent manner
- (2014) Walaa Alshafie et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Resolution of Cystic Fibrosis–related Diabetes with Ivacaftor Therapy
- (2014) Don Hayes et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis
- (2014) Steven M. Rowe et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Effects of Ivacaftor in Patients With Cystic Fibrosis Who Carry the G551D Mutation and Have Severe Lung Disease
- (2014) Peter J. Barry et al. CHEST
- Pulmonary Medication Adherence and Health-care Use in Cystic Fibrosis
- (2014) Alexandra L. Quittner et al. CHEST
- Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor
- (2014) Sonya L. Heltshe et al. CLINICAL INFECTIOUS DISEASES
- Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis
- (2014) Penny Whiting et al. HEALTH TECHNOLOGY ASSESSMENT
- The TMEM16A chloride channel as an alternative therapeutic target in cystic fibrosis
- (2014) Elvira Sondo et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
- (2014) Kris De Boeck et al. Journal of Cystic Fibrosis
- Some gating potentiators, including VX-770, diminish F508-CFTR functional expression
- (2014) G. Veit et al. Science Translational Medicine
- Potentiator ivacaftor abrogates pharmacological correction of F508 CFTR in cystic fibrosis
- (2014) D. M. Cholon et al. Science Translational Medicine
- Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders
- (2014) Michael Schlander et al. Journal of Comparative Effectiveness Research
- Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Eitan Kerem et al. Lancet Respiratory Medicine
- A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial
- (2014) Michael P Boyle et al. Lancet Respiratory Medicine
- Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp- CFTR mutation: a phase 3, open-label extension study (PERSIST)
- (2014) Edward F McKone et al. Lancet Respiratory Medicine
- Synthetic Aminoglycosides Efficiently Suppress Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations and Are Enhanced by Ivacaftor
- (2013) Xiaojiao Xue et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Pricing for Orphan Drugs
- (2013) Brian P. O’Sullivan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Treatment complexity in cystic fibrosis: Trends over time and associations with site-specific outcomes
- (2013) Gregory S. Sawicki et al. Journal of Cystic Fibrosis
- VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1
- (2013) Hong Yu Ren et al. MOLECULAR BIOLOGY OF THE CELL
- Mechanism-based corrector combination restores ΔF508-CFTR folding and function
- (2013) Tsukasa Okiyoneda et al. Nature Chemical Biology
- Nonsense-mediated mRNA decay: Inter-individual variability and human disease
- (2013) Lam Son Nguyen et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle
- (2013) Kang-Yang Jih et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HGF Stimulation of Rac1 Signaling Enhances Pharmacological Correction of the Most Prevalent Cystic Fibrosis Mutant F508del-CFTR
- (2012) Sónia Moniz et al. ACS Chemical Biology
- Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein
- (2012) Lihua He et al. FASEB JOURNAL
- Arsenic Promotes Ubiquitinylation and Lysosomal Degradation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Channels in Human Airway Epithelial Cells
- (2012) Jennifer M. Bomberger et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator VX-770 (Ivacaftor) Opens the Defective Channel Gate of Mutant CFTR in a Phosphorylation-dependent but ATP-independent Manner
- (2012) Paul D. W. Eckford et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Ivacaftor potentiation of multiple CFTR channels with gating mutations
- (2012) Haihui Yu et al. Journal of Cystic Fibrosis
- A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference
- (2012) Anissa Leonard et al. Journal of Cystic Fibrosis
- Increased Selectivity toward Cytoplasmic versus Mitochondrial Ribosome Confers Improved Efficiency of Synthetic Aminoglycosides in Fixing Damaged Genes: A Strategy for Treatment of Genetic Diseases Caused by Nonsense Mutations
- (2012) Jeyakumar Kandasamy et al. JOURNAL OF MEDICINAL CHEMISTRY
- Small heat shock proteins target mutant cystic fibrosis transmembrane conductance regulator for degradation via a small ubiquitin-like modifier–dependent pathway
- (2012) Annette Ahner et al. MOLECULAR BIOLOGY OF THE CELL
- Genome-wide RNAi screening identifies human proteins with a regulatory function in the early secretory pathway
- (2012) Jeremy C. Simpson et al. NATURE CELL BIOLOGY
- Rescue of nonsense mutations by amlexanox in human cells
- (2012) Sara Gonzalez-Hilarion et al. Orphanet Journal of Rare Diseases
- Hot off the breath: ‘I've a cost for’—the 64 million dollar question: Table 1
- (2012) Andrew Bush et al. THORAX
- Mechanisms of CFTR Folding at the Endoplasmic Reticulum
- (2012) Soo Jung Kim et al. Frontiers in Pharmacology
- Managing Cystic Fibrosis
- (2011) Malena Cohen-Cymberknoh et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Identification of a NBD1-Binding Pharmacological Chaperone that Corrects the Trafficking Defect of F508del-CFTR
- (2011) Heidi M. Sampson et al. CHEMISTRY & BIOLOGY
- Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis
- (2011) M. Wilschanski et al. EUROPEAN RESPIRATORY JOURNAL
- Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54
- (2011) Steven M. Rowe et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation
- (2011) Bonnie W. Ramsey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
- (2011) F. Van Goor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for theF508del-CFTRmutation
- (2011) J P Clancy et al. THORAX
- CFTR: folding, misfolding and correcting the ΔF508 conformational defect
- (2011) Gergely L. Lukacs et al. TRENDS IN MOLECULAR MEDICINE
- Influence of cell background on pharmacological rescue of mutant CFTR
- (2010) Nicoletta Pedemonte et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis
- (2010) Isabelle Sermet-Gaudelus et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- A Stabilizing Influence: CAL PDZ Inhibition Extends the Half-Life of ΔF508-CFTR
- (2010) Patrick R. Cushing et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- A new complex allele of the CFTR gene partially explains the variable phenotype of the L997F mutation
- (2010) Marco Lucarelli et al. GENETICS IN MEDICINE
- Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening
- (2010) Ori Kalid et al. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
- Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane
- (2010) T. Okiyoneda et al. SCIENCE
- Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis
- (2010) A. Prayle et al. THORAX
- N-glycans are direct determinants of CFTR folding and stability in secretory and endocytic membrane traffic
- (2009) Rina Glozman et al. JOURNAL OF CELL BIOLOGY
- Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis
- (2009) Darren M Hutt et al. Nature Chemical Biology
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
- (2009) F. Van Goor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CFTR Delivery to 25% of Surface Epithelial Cells Restores Normal Rates of Mucus Transport to Human Cystic Fibrosis Airway Epithelium
- (2009) Liqun Zhang et al. PLOS BIOLOGY
- Parallel Improvement of Sodium and Chloride Transport Defects by Miglustat (n-Butyldeoxynojyrimicin) in Cystic Fibrosis Epithelial Cells
- (2008) S. Noel et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model
- (2008) M. Du et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started